VERTEX PHARMACEUTICALS INCORPORATED Funds and ETFs Vertex Pharmaceuticals Incorporated
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 428.6 USD | -0.31% |
|
+4.47% | +5.33% |
| May. 14 | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 | MT |
| May. 10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
ETFs positioned on Vertex Pharmaceuticals Incorporated
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.50% | 92 M€ | +0.06% | - | |
| 0.48% | 219 M€ | +17.17% | - | |
| 0.48% | 1,448 M€ | -.--% | - | |
| 0.47% | 330 M€ | -.--% | ||
| 0.44% | 36 M€ | +22.19% | ||
| 0.42% | 9 M€ | +9.41% | ||
| 0.39% | 85 M€ | +11.59% | - | |
| 0.38% | 25 M€ | +4.02% | - | |
| 0.35% | 655 M€ | -.--% | - | |
| 0.35% | 1,174 M€ | +23.54% | ||
| 0.35% | 273 M€ | -.--% | ||
| 0.35% | 375 M€ | +8.28% | ||
| 0.35% | 368 M€ | +20.01% | - | |
| 0.34% | 276 M€ | +11.40% | - | |
| 0.32% | 559 M€ | +14.30% | ||
| 0.32% | 1,848 M€ | +18.39% | - | |
| 0.32% | 1 M€ | +0.04% | ||
| 0.32% | 2,383 M€ | +12.78% | ||
| 0.30% | 26 M€ | +20.63% | - | |
| 0.30% | 1,487 M€ | +7.21% | - | |
| 0.28% | 50 M€ | +9.54% | ||
| 0.28% | 744 M€ | +8.55% | ||
| 0.28% | 8 M€ | +5.15% | - | |
| 0.25% | 1 M€ | -.--% | ||
| 0.25% | 36 M€ | +2.97% | - | |
| 0.23% | 6 M€ | +17.98% | - | |
| 0.23% | 121 M€ | +7.29% | - | |
| 0.22% | 17 M€ | +4.20% | - | |
| 0.22% | 34 M€ | +11.62% | - | |
| 0.22% | 35 M€ | +8.00% | - |
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
09:00am
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
428.6
USD
Average target price
462.6
USD
Spread / Average Target
+7.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B | |
| +289.58% | 7.98B |
- Stock Market
- Equities
- VRTX Stock
- Funds and ETFs Vertex Pharmaceuticals Incorporated